2.
非黑棘皮病及黑棘皮病HOMA-IR、WBISI、IGI、HOMA-β比较
Comparison of HOMA-IR, WBISI, IGI and HOMA-β among male and female patients with NAN and AN
| Group | Female NAN | Female AN | Male NAN | Male AN |
| HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; IGI: The insulinogenic index; HOMA-β: Homoeostasis Model Assessment of β-cell function; WBISI: Whole body insulin sensitivity index. Compared with Q1 in female and compared with Q4 in male, aP < 0.05, bP < 0.01. Compared with NAN quartile groupings, cP < 0.05, dP < 0.01. NAN: Non-acanthosis nigrican; AN: Acanthosis nigrican. | ||||
| n | 227 | 137 | 146 | 129 |
| Age (year) | 30.76±7.62 | 28.37±6.84 | 32.23±9.12 | 28.26±6.43 |
| HOMA-IR | ||||
| Q1 | 3.76 (2.69, 6.38) | 6.60 (5.56, 11.06) | 7.25 (4.98, 9.87) | 8.45 (7.01, 12.29)c |
| Q2 | 3.81 (2.70, 5.39) | 5.68 (4.35, 8.52)c | 5.60 (3.48, 8.69) | 8.01 (6.60, 10.57) |
| Q3 | 5.06 (3.22, 7.21) | 6.92 (5.09, 10.29) | 4.27 (2.77, 6.95) | 6.51 (4.71, 9.10)d |
| Q4 | 5.82 (3.94, 7.71) | 6.64 (4.50, 10.18) | 4.36 (3.02, 7.05) | 8.65 (6.29, 13.22)d |
| WBISI | ||||
| Q1 | 0.0239 (0.0115, 0.0418) |
0.0091 (0.0074, 0.017)c |
0.0114 (0.0056, 0.0247)a |
0.0073 (0.0043, 0.0122) |
| Q2 | 0.0272 (0.014, 0.0378) |
0.0114 (0.0071, 0.0207)d |
0.0166 (0.0091, 0.0326) |
0.0091 (0.0045, 0.0145)d |
| Q3 | 0.0139 (0.0077, 0.0308) |
0.0116 (0.007, 0.0159) |
0.0240 (0.0128, 0.0357) |
0.0138 (0.0098, 0.0193)c |
| Q4 | 0.0151 (0.0059, 0.0265)a |
0.0112 (0.0071, 0.0161)c |
0.0233 (0.0119, 0.0403) |
0.0103 (0.0071, 0.0161)d |
| IGI | ||||
| Q1 | 20.63 (11.84, 37.15) |
39.43 (16.09, 69.84)c |
23.23 (8.27, 48.00) |
36.24 (22.73, 48.97) |
| Q2 | 25.93 (12.82, 48.39) |
21.33 (14.86, 42.33) |
33.28 (12.52, 64.48) |
45.30 (15.01, 97.05) |
| Q3 | 27.69 (14.26, 41.59) |
35.95 (15.70, 46.47) |
32.24 (15.43, 42.64) |
39.25 (26.28, 53.63)c |
| Q4 | 36.94 (19.9, 53.98) |
42.52 (13.99, 61.81) |
22.56 (14.60, 40.41) |
30.72 (15.75, 43.25) |
| HOMA-β | ||||
| Q1 | 184.69 (117.56, 290.63) |
321.12 (194.06, 445.35) |
253.51 (117.36, 445.94) |
368.85 (290.43, 558.06)d |
| Q2 | 183.40 (130.03, 268.43) |
263.32 (173.22, 345.03) |
228.00 (107.27, 274.67) |
396.27 (291.79, 575.87)d |
| Q3 | 228.47 (170.09, 287.81) |
288.78 (197.37, 463.41) |
207.86 (142.44, 299.61) |
403.45 (209.85, 541.83)d |
| Q4 | 332.40 (187.49, 442.54) |
423.20 (211.75, 485.38) |
218.58 (115.81, 285.02) |
370.19 (198.65, 419.38)d |